Elimination of HIV-1 infection by treatment with a doxorubicin-conjugated anti-envelope antibody
Authors:
- Susanne JohanssonSJSusanne Johansson
- David M GoldenbergDGDavid M Goldenberg
- Gary L GriffithsGGGary L Griffiths
- Britta WahrenBWBritta Wahren
- Jorma HinkulaJHJorma Hinkula
- 3 October 2006
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 20 (15) , 1911-1915
Abstract
To test the efficacy of an immunoconjugate against HIV-1. : A murine monoclonal antibody against the envelope antigen of HIV (P4/D10) was conjugated with the conventional anticancer drug, doxorubicin, and tested against infectious virus and infected cells, both in vitro and in vivo. P4/D10 antibody was incubated with free virus (neutralization) or HIV-infected cells (inhibition) and the resulting infection was measured by a p24 capture enzyme-linked immunosorbent assay. In an HIV-1/MuLV murine challenge model, the ability of the conjugate to inhibit infection in vivo was measured. Doxorubicin-conjugated P4/D10 neutralized HIV-1IIIB and eliminated intercellular spread and HIV replication in infected Jurkat cells in vitro. The conjugate also protected mice from challenge with HIV-1IIIB/MuLV at an eightfold lower concentration than needed for free antibody, whereas no effects were observed for comparable doses of free drug or irrelevant conjugate controls. This indicates that doxorubicin is concentrated to HIV-infected cells by the P4/D10 antibody, significantly (P = 0.0001) contributing to HIV elimination. This concept could also be adapted to eradicate remaining antigen-expressing T cells in patients treated with antiretroviral therapy.Keywords
This publication has 21 references indexed in Scilit:
- Arming antibodies: prospects and challenges for immunoconjugatesNature Biotechnology, 2005
- Anti-CD74 Antibody-Doxorubicin Conjugate, IMMU-110, in a Human Multiple Myeloma Xenograft and in MonkeysClinical Cancer Research, 2005
- Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodiesNature Medicine, 2005
- An anti-CD45RO immunotoxin kills HIV-latently infected cells from individuals on HAART with little effect on CD8 memoryProceedings of the National Academy of Sciences, 2004
- In Vivo Efficacy of Anti-Glycoprotein 41, But Not Anti-Glycoprotein 120, Immunotoxins in a Mouse Model of HIV InfectionThe Journal of Immunology, 2003
- Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in UgandaAIDS, 2002
- The Challenge of Viral Reservoirs in HIV-1 InfectionAnnual Review of Medicine, 2002
- Dose-response resistance to HIV-1/MuLV pseudotype virus ex vivo in a hairpin ribozyme transgenic mouse modelProceedings of the National Academy of Sciences, 1999
- Reconsidering targeted toxins to eliminate HIV infection: You gotta have HAARTProceedings of the National Academy of Sciences, 1998
- Specificity and properties of MAb RS7‐3G11 and the antigen defined by this pancarcinoma monoclonal antibodyInternational Journal of Cancer, 1993